Nuvation Bio Inc (NUVB)

Nuvation Bio Inc (NUVB) is a Biotechnology company in the Healthcare sector listed on the NYSE.

As of Oct 23, 2026: market cap $1.7B; returns 1 day -2.8%, 1 week +2.7%, 1 year +4.1%.

Nuvation Bio Inc. is a global oncology company focused on developing and commercializing novel therapies for difficult-to-treat cancers. Its primary revenue source is IBTROZI® (taletrectinib), a highly selective, next-generation oral ROS1 inhibitor. IBTROZI is approved for advanced ROS1-positive (ROS1+) non-small cell lung cancer (NSCLC) in the U.S., China, and Japan.

Groups NUVB belongs to

• Oncology
• Biotechnology
• Healthcare
• Biopharmaceutical
• Pharmaceuticals
• Commercial Stage Biotech
• Cancer Therapeutics
• Life Sciences
• Commercial Stage
• Strategic Partnerships

NUVB financial model: income statement, cash flow and balance sheet